[{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"46bd478e-b8d0-4e9c-a5fd-b1d6d75d3215","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975700","created_at":"2021-01-18T14:37:44.830Z","updated_at":"2024-07-02T16:35:10.337Z","phase":"","brief_title":"A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma","source_id_and_acronym":"NCT02975700","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/31/2017","start_date":" 01/31/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-10"},{"id":"31a7eaae-6a8f-4399-b8b3-72967fb1b821","acronym":"PIANO","url":"https://clinicaltrials.gov/study/NCT02071940","created_at":"2021-01-18T09:32:46.152Z","updated_at":"2024-07-02T16:36:26.459Z","phase":"Phase 2","brief_title":"PLX3397 KIT in Acral aNd mucOsal Melanoma","source_id_and_acronym":"NCT02071940 - PIANO","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 03/02/2021","primary_completion_date":" 03/02/2021","study_txt":" Completion: 03/02/2021","study_completion_date":" 03/02/2021","last_update_posted":"2021-08-12"},{"id":"b4bb2d6f-d75f-4210-91cf-04cc081ab22c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291288","created_at":"2024-02-16T08:18:36.953Z","updated_at":"2024-07-02T16:36:30.252Z","phase":"Phase 1","brief_title":"Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)","source_id_and_acronym":"NCT03291288","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 02/26/2018","start_date":" 02/26/2018","primary_txt":" Primary completion: 09/26/2018","primary_completion_date":" 09/26/2018","study_txt":" Completion: 04/16/2021","study_completion_date":" 04/16/2021","last_update_posted":"2021-05-14"},{"id":"75142721-76ff-4041-81af-9cb27af5e46a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03158103","created_at":"2021-01-18T15:34:11.495Z","updated_at":"2024-07-02T16:36:30.929Z","phase":"Phase 1","brief_title":"A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)","source_id_and_acronym":"NCT03158103","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFR wild-type","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Turalio (pexidartinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 04/15/2017","start_date":" 04/15/2017","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 04/28/2021","study_completion_date":" 04/28/2021","last_update_posted":"2021-04-30"},{"id":"8ec9609c-bdca-4f8d-83b7-7ecf4570d511","acronym":"","url":"https://clinicaltrials.gov/study/NCT01596751","created_at":"2021-01-18T06:49:32.020Z","updated_at":"2024-07-02T16:36:43.054Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01596751","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Turalio (pexidartinib)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 07/12/2012","start_date":" 07/12/2012","primary_txt":" Primary completion: 07/05/2017","primary_completion_date":" 07/05/2017","study_txt":" Completion: 07/05/2019","study_completion_date":" 07/05/2019","last_update_posted":"2020-07-17"},{"id":"ed8f9de5-8ed4-4b2c-9b7b-2e14ed4bf9e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349049","created_at":"2021-01-17T17:49:47.194Z","updated_at":"2024-07-02T16:36:49.347Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01349049","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 11/21/2011","start_date":" 11/21/2011","primary_txt":" Primary completion: 01/20/2015","primary_completion_date":" 01/20/2015","study_txt":" Completion: 01/09/2018","study_completion_date":" 01/09/2018","last_update_posted":"2020-03-02"}]